Telithromycin

Generic Name
Telithromycin
Brand Names
Ketek
Drug Type
Small Molecule
Chemical Formula
C43H65N5O10
CAS Number
191114-48-4
Unique Ingredient Identifier
KI8H7H19WL
Background

Telithromycin, a semi-synthetic erythromycin derivative, belongs to a new chemical class of antibiotics called ketolides. Ketolides have been recently added to the macrolide-lincosamide-streptogramin class of antibiotics. Similar to the macrolide antibiotics, telithromycin prevents bacterial growth by interfering with bacterial protein synthesis. Telithromycin binds to the 50S subunit of the 70S bacterial ribosome and blocks further peptide elongation. Binding occurs simultaneously at to two domains of 23S RNA of the 50S ribosomal subunit, domain II and V, where older macrolides bind only to one. It is used to treat mild to moderate respiratory infections.

Indication

临床主要用于敏感菌所致的呼吸道感染,包括社区获得性肺炎、慢性支气管炎、急性上颌窦咽炎及扁桃体炎。

Associated Conditions
Mild community-acquired pneumonia, Moderate Community acquired pneumonia
Associated Therapies
-

Ketek in CAP / AECB in Ambulatory Adult Patients

First Posted Date
2007-10-19
Last Posted Date
2007-11-14
Lead Sponsor
Sanofi
Target Recruit Count
174
Registration Number
NCT00546676

Telithromycin: in the Treatment of Acute Exacerbation of Chronic Bronchitis in Adult Outpatients With COPD

Phase 4
Completed
Conditions
First Posted Date
2007-10-02
Last Posted Date
2012-02-17
Lead Sponsor
Sanofi
Target Recruit Count
668
Registration Number
NCT00538148

Telithromycin, Treating Adult Outpatients With Mild to Moderate Community-acquired Pneumonia (CAP) in High Bacterial Resistance Areas

Phase 4
Completed
Conditions
First Posted Date
2007-10-02
Last Posted Date
2012-02-17
Lead Sponsor
Sanofi
Target Recruit Count
978
Registration Number
NCT00538018

AMS VS MOXI Ketek vs Avelox in AMS

Phase 3
Completed
Conditions
First Posted Date
2007-10-01
Last Posted Date
2012-02-17
Lead Sponsor
Sanofi
Target Recruit Count
351
Registration Number
NCT00537563
Locations
🇺🇸

Sanofi-Aventis, Bridgewater, New Jersey, United States

Controlled Trial: 5-day Course of Telithromycin Versus Doxycycline for the Treatment of Mild to Moderate Scrub Typhus

Phase 3
Completed
Conditions
First Posted Date
2006-07-12
Last Posted Date
2019-02-08
Lead Sponsor
Dong-Min Kim
Target Recruit Count
92
Registration Number
NCT00351182
Locations
🇰🇷

Chosun University Hospital, Gwangju, Jeonnam, Korea, Republic of

Intrapulmonary Pharmacokinetics of Antibiotics

Phase 4
Terminated
Conditions
First Posted Date
2006-04-18
Last Posted Date
2009-02-13
Lead Sponsor
University of Illinois at Chicago
Target Recruit Count
35
Registration Number
NCT00315601
Locations
🇺🇸

Pulmonary Associates PA, Phoenix, Arizona, United States

TELI TAD - Telithromycin in Tonsillitis in Adolescents and Adults

Phase 3
Terminated
Conditions
First Posted Date
2006-04-18
Last Posted Date
2009-04-03
Lead Sponsor
Sanofi
Target Recruit Count
233
Registration Number
NCT00315549
Locations
🇨🇷

Sanofi-Aventis, San Jose, Costa Rica

TELI COM - Telithromycin in Children With Otitis Media

First Posted Date
2006-04-17
Last Posted Date
2009-04-03
Lead Sponsor
Sanofi
Target Recruit Count
1500
Registration Number
NCT00315003
Locations
🇵🇪

Sanofi-Aventis, Lima, Peru

Telithromycin in Acute Exacerbation of Chronic Bronchitis

Phase 4
Terminated
Conditions
Interventions
First Posted Date
2006-02-07
Last Posted Date
2009-12-09
Lead Sponsor
Sanofi
Target Recruit Count
54
Registration Number
NCT00288223
Locations
🇹🇷

Sanofi-Aventis, Istanbul, Turkey

TELICAST : Telithromycin in Acute Exacerbations of Asthma

Phase 3
Completed
Conditions
First Posted Date
2006-01-09
Last Posted Date
2009-09-15
Lead Sponsor
Sanofi
Registration Number
NCT00273520
© Copyright 2024. All Rights Reserved by MedPath